PERSEUS --- 2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

PERSEUS --- 使用全新的计算机断层扫描方法针对转移性疾病进行基于 2D 材料的多重肿瘤治疗

• 批准号: 10073017
• 金额: $ 28.3万
• 依托单位: QED FILM & STAGE PRODUCTIONS LTD
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10073017
• 关键词: PERSEUS; 2D; Material; Based; Multiple

PERSEUS is developing a novel nanotechnology-based cancer treatment for deep-seated, clinically unmanageable, drug-resistant, and metastatic tumours. Practical use of nanotechnology in clinical cancer care is still in its infancy, its full potential yet to be realised. The treatment is based on a novel nano-system (NS) made of multifunctional 2D-layered nanocrystals. The NS enables, under activation by computed tomography (CT) X-rays, an effective multimodal therapy with minimal or no adverse effects. This novel paradigm uses CT X-rays not to eradicate cancer, but to trigger and to image the NS that locally activates non-mutagenic oncolytic mechanisms. The therapeutic effect is due to the conversion of low energy X-rays from CT scanners into heat, reactive oxygen species, and radiosensitising agents. X-ray irradiation can also induce immunogenic cell death with the exposure or release of neo-antigens to trigger an anti-cancer immune response. The use of X-rays makes it possible to reach deep-seated tumours that are inaccessible by visible or near-infrared light-based therapies. In other words, CT is the spark that lights the match. This is a radical vision for an ambitious and high-risk project. The project targets a range of cancer types, including metastatic triple negative breast cancer, hepatocellular carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma. The NS is biocompatible and also totally inactive in the absence of CT radiation, i.e. the NS becomes active only where the CT beam is delivered, hence minimising side effects at distal sites. The therapy is agnostic to the type of cancer and to gender incidence because it doesn't affect the body biochemistry. This is a second change of paradigm. The vision behind PERSEUS is pursued by a multidisciplinary team composed of physicists, chemists, chemical engineers, biologists, physicians, pharmacologists, and radiologists, working together to develop an innovative nanotechnological approach to address unmet clinical needs.

Perseus正在开发一种新型的基于纳米技术的癌症治疗方法，用于深处，临床上不可控制，耐药性和转移性肿瘤。纳米技术在临床癌症护理中的实际使用仍处于起步阶段，其全部潜力尚未实现。该处理是基于由多功能2D层纳米晶体制成的新型纳米系统（NS）。 NS在通过计算机断层扫描（CT）X射线激活下启用，这是一种有效的多模式疗法，具有最小或没有不利影响。这种新颖的范式使用CT X射线不是消除癌症，而是触发并成像局部激活非溶血肿瘤机制的NS。治疗作用是由于低能X射线从CT扫描仪转化为热量，活性氧和放射性敏感剂。 X射线照射还可以通过暴露或释放新抗原引发抗癌免疫反应，从而诱导免疫原性死亡。 X射线的使用使得无法通过可见或近红外光疗法无法访问的深处肿瘤。换句话说，CT是点燃比赛的火花。这是一个雄心勃勃的高风险项目的根本愿景。该项目针对一系列癌症类型，包括转移性三重阴性乳腺癌，肝细胞癌，大肠癌，胰腺导管腺癌。 NS是生物相容性的，并且在没有CT辐射的情况下也完全不活跃，即仅在CT梁传递的情况下才能活跃，从而最大程度地减少了远端位点的副作用。该疗法对癌症类型和性别发病率不可知，因为它不会影响人体生物化学。这是范式的第二个变化。由物理学家，化学家，化学工程师，生物学家，医师，药理学家和放射学家组成的多学科团队追求了珀尔修斯背后的愿景，共同开发了一种创新的纳米技术方法来满足未满足临床需求的创新纳米技术。